Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without paracentesis in DME
NCT05861466Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2023
- Primary completion
- Nov 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in diabetic macular edema (DME), sponsored by Ain Shams University. Primary endpoint: Acute change in angiographic parameters at 1 day. Started Jan 2023; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05861466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861466.